Kidney Cancer

Bayer and Onyx have ongoing clinical trials for individuals with kidney cancer. For a more comprehensive list of Nexavar® (sorafenib) clinical trials in a variety of tumor types, please visit clinicaltrials.gov or call 866-639-2827.

Phase 3 Study of Nexavar Versus Sunitinib in Adjuvant Setting - ASSURE *
Study Design: Randomized, placebo-controlled study
Patients: Patients with advanced RCC that has been removed by surgery
Purpose: To compare the efficacy of Nexavar versus sunitinib versus placebo by assessing the differences in disease progression and overall survival
Location: Various sites in the United States and Canada

Phase 3 Study of Nexavar for 3 years vs. 1 year in Adjuvant Setting - SORCE *
Study Design: Randomized, placebo-controlled study
Patients: Patients with advanced RCC that has been removed by surgery
Purpose: To compare the efficacy of Nexavar treatment for 3 years vs. Nexavar treatment for 1 year vs. placebo by assessing differences in disease-free survival, as well as evaluate other measures of efficacy and safety
Location: United Kingdom
* Not a company-sponsored trial

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204